1. Home
  2. KBH vs ARQT Comparison

KBH vs ARQT Comparison

Compare KBH & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KB Home

KBH

KB Home

HOLD

Current Price

$56.12

Market Cap

3.8B

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$22.74

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBH
ARQT
Founded
1957
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.3B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
KBH
ARQT
Price
$56.12
$22.74
Analyst Decision
Hold
Strong Buy
Analyst Count
14
6
Target Price
$56.17
$34.00
AVG Volume (30 Days)
1.2M
958.4K
Earning Date
03-24-2026
05-06-2026
Dividend Yield
1.80%
N/A
EPS Growth
N/A
88.79
EPS
0.52
N/A
Revenue
$4,547,002,000.00
$376,072,000.00
Revenue This Year
N/A
$34.85
Revenue Next Year
$9.23
$29.39
P/E Ratio
$106.77
N/A
Revenue Growth
N/A
91.34
52 Week Low
$48.17
$12.42
52 Week High
$68.71
$31.77

Technical Indicators

Market Signals
Indicator
KBH
ARQT
Relative Strength Index (RSI) 60.49 42.73
Support Level $55.18 $22.56
Resistance Level $63.51 $23.46
Average True Range (ATR) 1.40 0.89
MACD 0.85 -0.04
Stochastic Oscillator 85.61 10.93

Price Performance

Historical Comparison
KBH
ARQT

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: